Do you want to read an article? Please log in or register.
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis
Rheumatoid Arthritis
Related content
Rheumatoid Arthritis
Transcriptional profiling of leukocytes from rheumatoid arthritis patients before and after anti-tumor necrosis factor therapy: A comparison of anti-nuclear antibody positive and negative subsets
Exp Ther Med.
Davis LS, Reimold AM
doi: 10.3892/etm.2017.4265.
Rheumatoid Arthritis
IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis
Mod Rheumatol.
Takasugi K, Nishida K, Natsumeda M, Yamashita M, Yamamoto W, Ezawa K
doi: 10.1080/14397595.
Rheumatoid Arthritis
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials
Ann Rheum Dis
Winthrop KL, Nash P, Yamaoka K, Mysler E, Khan N, Camp HS, Song Y, Suboticki JL, Curtis JR
doi: 10.1136/annrheumdis-2021-220822
Rheumatoid Arthritis
Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice
Clin Exp Rheumatol.
Leon L, Gomez A, Vadillo C, Pato E, Rodriguez-Rodriguez L, Jover JA, Abasolo L
Rheumatoid Arthritis
Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial
JAMA.
Gottenberg JE, Brocq O, Perdriger A, Lassoued S, Berthelot JM, Wendling D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B, Constantin AL, Mariette X, Morel J, Gilson M, Cormier G, Salmon JH, Rist S, Lioté F, Marotte H, Bonnet C, Marcelli C, Sellam J, Meyer O, Solau-Gervais E, Guis S, Ziza JM, Zarnitsky C, Chary-Valckenaere I, Vittecoq O, Saraux A, Pers YM, Gayraud M, Bolla G, Claudepierre P, Ardizzone M, Dernis E, Breban MA, Fain O, Balblanc JC, Aberkane O, Vazel M, Back C, Candon S, Chatenoud L, Perrodeau E, Sibilia J, Ravaud P
doi: 10.1001/jama.2016.13512.
COMMENTED
Rheumatoid Arthritis
Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity
Rheumatology (Oxford).
Lamers-Karnebeek FBG, Jacobs JWG, Radstake TRDJ, van Riel PLCM, Jansen TL
doi: 10.1093/rheumatology/
COMMENTED
PsoriasisRheumatoid Arthritis
Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
doi: 10.1016/S2468-1253(19)30362-0.
Rheumatoid Arthritis
Effectiveness of whole-body magnetic resonance imaging for the efficacy of biologic anti-rheumatic drugs in patients with rheumatoid arthritis: A retrospective pilot study.
Mod Rheumatol.
Kono M, Kamishima T, Yasuda S, Sakamoto K, Abe S, Noguchi A, Watanabe T, Shimizu Y, Oku K, Bohgaki T, Amengual O, Horita T, Atsumi T
doi: 10.1080/
Rheumatoid Arthritis
Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study
Lancet Rheumatol.
Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, Alser O, Alshammari TM, Biedermann P, Banda JM, Burn E, Casajust P, Conover MM, Culhane AC, Davydov A, DuVall SL, Dymshyts D, Fernandez-Bertolin S, Fišter K, Hardin J, Hester L, Hripcsak G, Kaas-Hansen BS, Kent S, Khosla S, Kolovos S, Lambert CG, van der Lei J, Lynch KE, Makadia R, Margulis AV, Matheny ME, Mehta P, Morales DR, Morgan-Stewart H, Mosseveld M, Newby D, Nyberg F, Ostropolets A, Park RW, Prats-Uribe A, Rao GA, Reich C, Reps J, Rijnbeek P, Sathappan SMK, Schuemie M, Seager S, Sena AG, Shoaibi A, Spotnitz M, Suchard MA, Torre CO, Vizcaya D, Wen H, de Wilde M, Xie J, You SC, Zhang L, Zhuk O, Ryan P, Prieto-Alhambra D, OHDSI-COVID-19 consortium
doi: 10.1016/S2665-9913(20)30276-9.